Association of Tralokinumab and Adalimumab: Good Tolerance and Efficacy in a Case of Severe Atopic Dermatitis and Juvenile Idiopathic Arthritis

ABSTRACT Atopic dermatitis is a chronic inflammatory and pruritic skin disease. The combination of tralokinumab with adalimumab in the treatment of inflammatory diseases had not yet been documented. It appears promising for treating severe atopic dermatitis in patients with juvenile idiopathic arthritis, offering significant improvement in skin symptoms as well as good clinical and biological tolerance. We report a case of severe atopic dermatitis successfully treated with tralokinumab, demonstrating good tolerance and effectiveness in a 17‐year‐old patient also on adalimumab for juvenile idiopathic arthritis.